[
  {
    "title": "Generate caps a strong month for biotech IPOs with $400M offering",
    "link": "https://www.biopharmadive.com/news/generate-biomedicines-ipo-price-biotech-ai-flagship-startup/813130/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-27T01:42:00.000Z",
    "summary": "The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years."
  },
  {
    "title": "STAT+: Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program",
    "link": "https://www.statnews.com/pharmalot/2026/02/26/justice-department-backs-abbvie-340b-hospitals-medicines-pharma/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T21:41:02.000Z",
    "summary": "DOJ is backing AbbVie in its battle to overturn a Colorado law that prohibits pharmaceutical companies from placing restrictions on the 340B drug discount program."
  },
  {
    "title": "STAT+: Cigna, extending reach into prescription drugs, acquires major pharmacy used by hospitals",
    "link": "https://www.statnews.com/2026/02/26/cigna-carepathrx-acquisition-vertical-integration/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T20:24:14.000Z",
    "summary": "Scoop: Cigna has acquired CarepathRx, a large pharmacy backed by private equity that dispenses prescription drugs to nearly 10% of U.S. hospitals."
  },
  {
    "title": "Listen: FDA turmoil, election intrigue, AI, and more",
    "link": "https://www.statnews.com/2026/02/26/listen-fda-turmoil-election-intrigue-ai-readout-loud/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T18:56:06.000Z",
    "summary": "On this week's Readout LOUD: Adam is joined by guest host Jared Holz to talk M&A, FDA turmoil, election intrigue, and more."
  },
  {
    "title": "CMS announces pause on new durable medical equipment suppliers",
    "link": "https://www.statnews.com/2026/02/26/cms-national-moratorium-durable-medical-equipment/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T18:09:50.000Z",
    "summary": "The Trump administration issued a nationwide moratorium on new suppliers for certain medical equipment, citing fraud."
  },
  {
    "title": "Everything you need to know about RFK Jr., MAHA, and ‘glypho-gate’",
    "link": "https://www.statnews.com/2026/02/26/glyphosate-herbicide-maha-backlash-alex-hogan-status-report/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T17:59:03.000Z",
    "summary": "This week on STATus Report, everything you need to know about RFK Jr., MAHA, and \"glypho-gate.\""
  },
  {
    "title": "FDA Grants Second Approval under the National Priority Voucher Pilot Program",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-grants-second-approval-under-national-priority-voucher-pilot-program",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-26T17:38:38.000Z",
    "summary": "The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program."
  },
  {
    "title": "Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial",
    "link": "https://www.biopharmadive.com/news/lilly-orforglipron-rybelsus-diabetes-study-results-glp-1/813209/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-26T17:10:00.000Z",
    "summary": "Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates."
  },
  {
    "title": "Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer",
    "link": "https://www.biopharmadive.com/news/bristol-myers-systimmune-adc-breast-cancer-results-china/813206/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-26T16:29:55.000Z",
    "summary": "The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth."
  },
  {
    "title": "STAT+: The nation’s MAHA mom lands in Congress, with some uncomfortable questions",
    "link": "https://www.statnews.com/2026/02/26/dc-diagnosis-the-nations-maha-mom-casey-means/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T16:23:45.000Z",
    "summary": "Casey Means' confirmation hearing, prior auth reforms are a priority, and other updates from D.C. Diagnosis"
  },
  {
    "title": "STAT+: What stands between brain implants and FDA approval?",
    "link": "https://www.statnews.com/2026/02/26/brain-computer-interface-fda-approval-challenges-health-tech/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T16:11:47.000Z",
    "summary": "In this edition of STAT Health Tech: The regulatory challenges faced by startups developing implanted brain-computer interfaces, and more."
  },
  {
    "title": "STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad",
    "link": "https://www.statnews.com/2026/02/26/makary-fda-rare-disease-vinay-prasad-cnbc/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T15:20:07.000Z",
    "summary": "FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and one of his deputies, Vinay Prasad, in an interview with CNBC."
  },
  {
    "title": "STAT+: FDA rejection is a reality check on agency rhetoric",
    "link": "https://www.statnews.com/2026/02/26/biotech-news-fda-rejection-for-rare-blood-cancer-therapy/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T14:37:38.000Z",
    "summary": "Sarepta CEO steps down, an experimental cell therapy rejection, and more biotech news"
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more",
    "link": "https://www.statnews.com/pharmalot/2026/02/26/fda-lilly-obesity-gilead-hiv-sarepta/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T14:07:15.000Z",
    "summary": "An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared"
  },
  {
    "title": "Questions on the agenda for ACIP’s next meeting",
    "link": "https://www.statnews.com/2026/02/26/health-news-the-next-acip-vaccine-meeting-agenda/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T13:08:31.000Z",
    "summary": "Casey Means faces off against Cassidy, a postponed vaccine advisory meeting, and more health news"
  },
  {
    "title": "Sarepta CEO Doug Ingram to retire, with company at a crossroads",
    "link": "https://www.biopharmadive.com/news/sarepta-doug-ingram-ceo-retire-duchenne/813169/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-26T13:00:00.000Z",
    "summary": "Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling Elevidys sales and emerging competitors to its core business."
  },
  {
    "title": "STAT+: Xenon’s seizure drug study reads out soon. Here’s what to expect",
    "link": "https://www.statnews.com/2026/02/26/xenon-seizures-azetukalner-richard-pops-alkermes/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T11:30:00.000Z",
    "summary": "Xenon Pharmaceuticals is developing a drug for the most common type of seizure experienced by people with epilepsy. Here's what to know."
  },
  {
    "title": "STAT+: Rare disease advocates fume over FDA’s mixed signals",
    "link": "https://www.statnews.com/2026/02/26/rare-disease-treatment-approval-fda-mixed-messages/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T09:30:00.000Z",
    "summary": "Families facing rare diseases feel whiplash over shifting and contradictory decisions by the FDA."
  },
  {
    "title": "Opinion: I had a brother with schizophrenia. I can’t stop thinking about Nick Reiner’s siblings",
    "link": "https://www.statnews.com/2026/02/26/nick-reiner-mental-illness-siblings-schizophrenia/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T09:30:00.000Z",
    "summary": "When mental illness strikes a family, siblings are often overlooked."
  },
  {
    "title": "STAT+: Brain implants: What’s standing in the way of pivotal trials, FDA approval",
    "link": "https://www.statnews.com/2026/02/26/brain-computer-interface-fda-regulatory-hurdles/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T09:30:00.000Z",
    "summary": "Thirty years after scientists demonstrated how brain implants can help rhesus monkeys move robotic limbs using only their mind, the clinical pathway for the technology is still a little out…"
  },
  {
    "title": "Opinion: I tried to design a clinical trial for a supplement. 5 things got in the way",
    "link": "https://www.statnews.com/2026/02/26/nutraceutical-clinical-trials-5-barriers-nutritional-supplement-research/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T09:30:00.000Z",
    "summary": "When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the industry."
  },
  {
    "title": "Trump administration pauses some Medicaid funding to Minnesota, citing fraud concerns",
    "link": "https://www.statnews.com/2026/02/25/trump-administration-pauses-medicaid-funds-minnesota/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T00:44:11.000Z",
    "summary": "Vice President JD Vance announced Wednesday that the Trump administration would “temporarily halt” some Medicaid funding to the state of Minnesota over fraud concerns."
  },
  {
    "title": "STAT+: Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade",
    "link": "https://www.statnews.com/2026/02/25/sarepta-ceo-doug-ingram-to-retire/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T00:27:40.000Z",
    "summary": "Sarepta's CEO will retire after a tumultuous decade in which Sarepta became a $15 billion company — and then that value collapsed."
  },
  {
    "title": "The therapeutic potential of orphan adhesion G-protein-coupled receptors",
    "link": "https://www.nature.com/articles/s41573-025-01371-6",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-26T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "Dose-finding and optimization in drug development for rare diseases",
    "link": "https://www.nature.com/articles/d41573-026-00035-3",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-26T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "Trump’s State of the Union trumpets healthcare greatest hits, but no new policies",
    "link": "https://www.biopharmadive.com/news/trump-state-of-the-union-healthcare-2026/813159/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T22:16:00.000Z",
    "summary": "In his lengthy address Tuesday night, the president touted his efforts to make drugs and insurance more affordable but steered clear of hot-button issues like vaccine access and the GOP’s Medicaid…"
  },
  {
    "title": "Surgeon general nominee and senator face off over vaccines and ‘shared decision-making’",
    "link": "https://www.statnews.com/2026/02/25/casey-means-bill-cassidy-face-off-on-vaccines/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T20:57:49.000Z",
    "summary": "Casey Means wanted to talk about chronic disease. But Bill Cassidy wanted to hear about her views on vaccines."
  },
  {
    "title": "STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA",
    "link": "https://www.statnews.com/2026/02/25/rare-disease-drug-fda-ebvallo/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-25T17:57:24.000Z",
    "summary": "Drugmakers thought they had the FDA's buy-in to approve a therapy to treat a type of cancer that can quickly turn deadly. The agency, however, rejected it."
  },
  {
    "title": "Alkermes’ Richard Pops to step down after three-decade run as CEO",
    "link": "https://www.biopharmadive.com/news/alkermes-richard-pops-ceo-succession-blair-jackson/813073/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T16:54:00.000Z",
    "summary": "One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it a frontrunner in developing a new narcolepsy drug."
  },
  {
    "title": "GSK to acquire 35Pharma in $950M deal for cardiovascular drug",
    "link": "https://www.biopharmadive.com/news/gsk-35pharma-acquire-pulmonary-hypertension-drug-activin-winrevair/813067/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T14:43:04.000Z",
    "summary": "The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair."
  },
  {
    "title": "15 states sue HHS over changes to childhood vaccine schedule",
    "link": "https://www.biopharmadive.com/news/15-states-sue-hhs-vaccine-schedule-changes-acip/813026/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T13:18:00.000Z",
    "summary": "The lawsuit seeks to reverse the abrupt overhaul of the U.S. immunization schedule as well as the federal government’s allegedly “unlawful” reformation of a key vaccine panel."
  },
  {
    "title": "With Vivtex deal, Novo gains a chance at better oral obesity drugs",
    "link": "https://www.biopharmadive.com/news/vivtex-novo-nordisk-oral-obesity-drugs-biologics/812754/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T13:00:00.000Z",
    "summary": "The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of oral biologic medicines."
  },
  {
    "title": "BreezeBio banks $60M to make more precise genetic medicines",
    "link": "https://www.biopharmadive.com/news/breezebio-genedit-series-b-diabetes-autoimmune/812976/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T12:00:00.000Z",
    "summary": "The company has shed its former “GenEdit” name and strategy in favor of a plan to develop its own medicines, starting with a potential tolerance-inducing treatment for Type 1 diabetes."
  },
  {
    "title": "Gilead pays US$7.8 billion for Arcellx’s next-generation CAR T candidate",
    "link": "https://www.nature.com/articles/d41573-026-00034-4",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-25T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-23T16:32:48.000Z",
    "summary": "The U.S. Food and Drug Administration today issued draft guidance for sponsors seeking approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety…"
  }
]
